borderline resectable pancreatic cancer
Conditions
Interventions
To investigate the frequency of histological curative resection following chemoradiation using Gemcitabine combined with IMRT for borderline resectable pancreatic cancer
Sponsors
Hepato-pamcreato-biliary Surgery and Transplantation, Graduate School of Medicine and Faculty of Medicine KyotoUniversity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with Histo-cytologically confirmed pancreatic cancer 2.Patients with radiologically defined patentially borderline resectable pancreatic cancer 3.Patients with Performance status of 0/1 4.Patients who have not undergone chemo and/or radiotherapyPatients with no metastatic disease confirmed by staging laparoscopy 5.Patiants who can oral intake 6.Patients with normal ECG findings 7.Patients with sustained organ function 8.Patients who received informed consent
Exclusion criteria
Exclusion criteria: 1) Patients with lung fibrosis or interstitional pneumonia 2) Patients who can not underwent radiation therapy because of past radiation therapy 3) Severe co-morbid diseases 4) Intractable pleural and pericardical effusion, or ascites 5) Patients with other active cancers 6)Pregnancy or insufficient contraception 7) severe mental illness 8) Patients seems inadequate for this study by investigator(s)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histological curative resection rate (R0 Ratio) | — |
Secondary
| Measure | Time frame |
|---|---|
| pathological responce rate, progression free survival, over all survival, incident of adverse event, mortality | — |
Countries
Japan
Contacts
Public ContactMasaki Mizumoto
Graduate School of Medicine and Faculty of Medicine KyotoUniversity Hepato-pancreato-biliary Surgery and Transplantation
Outcome results
None listed